Billiontoone (NASDAQ:BLLN) Insider Shan Riku Sakakibara Sells 4,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 4,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $140.21, for a total value of $560,840.00. Following the completion of the sale, the insider owned 200,000 shares of the company’s stock, valued at approximately $28,042,000. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Thursday, July 9th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $125.00, for a total transaction of $1,000,000.00.
• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $110.00, for a total transaction of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Stock Performance

Shares of NASDAQ:BLLN opened at $142.52 on Wednesday. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $144.27. The company has a market capitalization of $6.56 billion and a price-to-earnings ratio of 259.13. The firm’s 50-day moving average is $115.55 and its 200 day moving average is $93.87.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. During the same period in the previous year, the business earned ($0.39) EPS. The firm’s revenue for the quarter was up 83.8% on a year-over-year basis. Research analysts predict that Billiontoone, Inc. will post 0.92 EPS for the current year.

Wall Street Analyst Weigh In

BLLN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. raised their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Guggenheim began coverage on Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 target price on the stock. BTIG Research lowered their target price on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Billiontoone presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Hedge Funds Weigh In On Billiontoone

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Adams Street Partners LLC bought a new stake in shares of Billiontoone in the fourth quarter valued at about $140,063,000. Baillie Gifford & Co. bought a new stake in shares of Billiontoone in the 4th quarter valued at about $103,786,000. Wasatch Advisors LP lifted its position in shares of Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after purchasing an additional 148,446 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in Billiontoone during the fourth quarter valued at approximately $39,717,000. Finally, JPMorgan Chase & Co. bought a new position in Billiontoone in the fourth quarter worth approximately $32,078,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.